MLchartDataset catalogue

welgenaleucel

Term · Oncology and biomedicine · MLC-T-ONC-017556

A preparation of autologous T lymphocytes that are engineered to express a chimeric antigen receptor (CAR) composed of an anti-cluster of differentiation 19 (CD19) single chain variable fragment (scFv) linked to the signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration, welgenaleucel targets, binds to and induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.

Table 1. Record
IdentifierMLC-T-ONC-017556
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-017556",
  "term": "welgenaleucel",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that are engineered to express a chimeric antigen receptor (CAR) composed of an anti-cluster of differentiation 19 (CD19) single chain variable fragment (scFv) linked to the signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration, welgenaleucel targets, binds to and induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/welgenaleucel/"
}

Record 17,397 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.